Skip to main content

Food Allergy News and Research

Viaskin™ Peanut Patch Not Approved in Its Present Form - DBV to Request Meeting With FDA

DBV Technologies, a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the Company’s Biologics License Application (BLA) for investigational Viaskin™ Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.

Study Tests Best Ways to Remove Food Allergens From Surfaces

Many people are concerned about the food you can’t see – the food left on restaurant tables, school cafeteria tables and in the home kitchen . It’s a valid concern. Some cleaning methods don’t completely remove food allergens. A person with a food allergy may be at risk of having a serious allergic reaction (anaphylaxis) from cross-contact if they eat their food off that surface. The Food and Drug Administration (FDA) has done a study called “ Allergen Removal and Transfer Using Wiping and...

Dupixent® (Dupilumab) Shows Positive Results for Eosinophilic Esophagitis During Clinical Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints. Dupixent is the first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial.

Alert: Possible Malfunction of Amneal and Impax Laboratories Epinephrine Auto-Injector Devices

If you have received Amneal or Impax’s 0.3mg epinephrine auto-injector after December 20, 2018, should immediately visually inspect the auto-injector to confirm the presence of the yellow “stop collar” by following the instructions below. You can find photos to explain the steps in the letter sent to consumers . Epinephrine is a life-saving medicine for people with severe allergies. There are different devices available in the U.S. and each device has its own unique set of instructions.

Why It's Important to Carry Epinephrine With You Everywhere You Go When You Have Food Allergies

May is National Asthma and Allergy Awareness Month . May 10-16, 2020, is Food Allergy Awareness Week. The Asthma and Allergy Foundation of America (AAFA) and MedicAlert have teamed up to help you manage your child’s food allergies and prevent severe allergic reactions. (Kids With Food Allergies is a division of AAFA). We’re asking you to “ACT” to manage your child’s allergies: “A” means have an action plan for anaphylaxis. “C” reminds you to carry important medicines and have your child wear...

How an Action Plan Can Help You Treat Anaphylaxis

May is National Asthma and Allergy Awareness Month . May 10-16, 2020, is Food Allergy Awareness Week. The Asthma and Allergy Foundation of America (AAFA) and MedicAlert have teamed up to help you manage your child’s food allergies and prevent severe allergic reactions. (Kids With Food Allergies is a division of AAFA). We’re asking you to “ACT” to manage your child’s allergies: “A” means have an action plan for anaphylaxis. “C” reminds you to carry important medicines and have your child wear...

Alert: FDA Requests Removal of All Ranitidine Products (Zantac) From the Market

The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperature

Generic Montelukast and Singulair Will Now Carry Stronger Warning Label About Possible Side Effects

The U.S. Food and Drug Administration today announced that it is requiring a boxed warning – the agency’s most prominent warning – for montelukast (sold under the brand name Singulair and in generic form) to strengthen an existing warning about the risk of neuropsychiatric events associated with the drug, which is used to treat asthma and allergic rhinitis (hay fever).

Breaking News: FDA Approves Palforzia, a Ground-Breaking Peanut Allergy Oral Immunotherapy Treatment

On Jan. 31, 2020, the U.S. Food and Drug Administration (FDA) announced its approval of Aimmune Therapeutics’ peanut treatment, Palforzia, for children ages 4 to 17. This is big news for the food allergy community. Food allergies put a significant mental, social and financial burden on families. Until now, strict avoidance has been the only way to avoid allergic reactions. Palforzia may give many families managing peanut allergies more freedom and greater quality of life.

Peanut Patch Shows Positive Results During Clinical Trial

DBV Technologies, a clinical-stage biopharmaceutical company, today announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin® Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose (ED), which may decrease the chance of reacting to an accidental peanut exposure.

Post
Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
1235 South Clark Street Suite 305, Arlington, VA 22202
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×